Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28321777 | 0.83 | RXRA (0.34) | PPARGRXRARXRBRXRGIDO1 | |
| SCHEMBL14925339 | 0.83 | RXRA (0.45) | PPARGRXRARXRBRXRGIDO1 | |
| SCHEMBL14237735 | 0.79 | MRGPRX4 (0.43) | IDO1MRGPRX4NOTUM | |
| SCHEMBL1685381 | 0.78 | LTA4H (0.46) | PPARGRXRARXRBRXRGIDO1 | |
| SCHEMBL6535886 | 0.77 | TDP1 (0.43) | RXRARXRBRXRGALDH1A1TDP1 | |
| SCHEMBL14237535 | 0.77 | IDO1 (0.41) | PPARGIDO1MRGPRX4HTR1A | |
| SCHEMBL11048002 | 0.76 | LTA4H (0.45) | PPARGRXRARXRBRXRGIDO1 | |
| SCHEMBL9242571 | 0.76 | HSD11B1 (0.53) | PPARGRXRARXRBRXRGIDO1 | |
| SCHEMBL13951851 | 0.74 | IDO1 (0.50) | PPARGRXRARXRBRXRGIDO1 | |
| SCHEMBL1053934 | 0.74 | PPARG (0.41) | PPARGRXRARXRBRXRGIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732574-A | Preparation of thianthrene-5, 5,10, 10-tetraoxide derivative and organic electroluminescent device based on thianthrene-5, 5,10, 10-tetraoxide derivative | 中国科学院理化技术研究所 | 2016-07-06 | — | — | CN | claimed |
| CN-105693608-A | 2, 2-dimethyl-1, 3-indene dione derivatives and organic electroluminescent devices based thereon | 中国科学院理化技术研究所 | 2016-06-22 | — | — | CN | claimed |
| CN-105220473-A | A kind of water-proof aagent and application thereof | HOPERISE TEXTILES CO LTD QUANZHOU | 2016-01-06 | — | — | CN | claimed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12527763-B2 | Pyrrole amide compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-01-20 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6080870-A | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0938471-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5929097-A | INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0891333-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998016503-A2 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997036875-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | PPARG 1799/4885RXRA 612/4885RXRB 565/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | PPARG 2152/4885RXRA 3829/4885RXRB 2532/4885 |
| US-12527763-B2 | Pyrrole amide compound and use thereof | NR3C2, AVPR2, MC2R | PPARG 167/4885RXRA 528/4885RXRB 447/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | PPARG 1277/4885RXRA 2995/4885RXRB 3014/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | PPARG 3101/4885RXRA 2976/4885RXRB 3093/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | PPARG 38/4885RXRA 39/4885RXRB 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.